FLASH Radiotherapy — Treatment in Less Than a Second

Sun rays breaking through dramatic cloud formation in a clear blue sky

General information only — not medical advice. FLASH is still experimental. It is not a standard treatment, and it is only available inside clinical trials. Please follow your own treating team’s advice.

FLASH radiotherapy has been in the news a lot, and it is easy to see why: the idea is to give the whole dose of radiation in less than a second. This article explains what FLASH is, why scientists are excited about it, what has actually been tested in people so far, and what it does — and does not — mean for patients today.

What is FLASH?

FLASH is not a different kind of radiation. It uses the same radiation as standard radiotherapy — most often protons, and in early work, electrons. What is different is the speed. In standard radiotherapy, each treatment session takes minutes, and the dose is given at a normal rate. In FLASH, the same dose is given at an ultra-high dose rate — in a fraction of a second, in one very short burst. To give you a sense of the difference: a session that takes a few minutes with standard radiotherapy could take less than a second with FLASH. That is more than a hundred times faster. The treatment itself is otherwise similar. You lie still on a treatment couch, the machine is aimed carefully at the tumour, and the team watches you from outside the room. The difference is in how fast the dose arrives — not in what the radiation is.

Why are scientists excited?

The excitement comes from animal studies. In laboratory animals, researchers found something unexpected: when radiation was given at FLASH speed, the tumour was still damaged, but the healthy tissue around it seemed to be harmed less than with standard radiotherapy. This possible protective effect on healthy tissue is called the FLASH effect. If it is real in people, it could matter a great deal — especially for tumours sitting close to important organs, or for cancers that have already been treated with radiotherapy once, where there is very little room to give more radiation safely. Scientists do not yet fully understand why the FLASH effect happens. One idea is that the very fast burst briefly uses up the oxygen in the healthy tissue, and that this makes the tissue temporarily less sensitive to radiation — while the tumour, which already has low oxygen, is affected much as usual. That is a theory, not a proven explanation, and other explanations are also being studied. The honest position is this: the FLASH effect has been seen in animals, and it is a promising idea. Whether it works the same way in people is exactly what the current trials are trying to find out.

What has been tested in people so far?

FLASH in people is very new, and the studies so far have been small. They were designed mainly to answer a first question: can FLASH be given safely, and does the machine work as intended? They were not designed to prove that FLASH is better than standard radiotherapy.

The first person treated with FLASH was in 2019, in Switzerland — a single patient with a skin lymphoma, treated with electron FLASH. The treatment was given safely, and the result encouraged further research.

FAST-01 was the first trial of proton FLASH in people. It treated a small group of adults whose cancer had spread to the bones of the arms or legs and was causing pain. Each person received a single FLASH treatment. Pain improved for most of the treated sites, and the side effects reported were mild. Because there was no comparison group receiving standard radiotherapy, the trial could not show that FLASH relieved pain better than standard treatment — only that it could be given safely and was feasible.

FAST-02 extended the same idea to bone metastases in the chest — the ribs, collarbone, breastbone, and shoulder blade, close to the heart and lungs. Again, a small group received a single FLASH treatment, pain improved for most, and no moderate or severe treatment-related side effects were reported over the follow-up period. Again, there was no comparison group, so it does not prove FLASH is better — only that it could be delivered safely in a more difficult area.

Conformal FLASH is the next step. Early FLASH could only treat fairly simple shapes. Conformal FLASH aims to shape the ultra-fast dose precisely around a three-dimensional tumour — the kind of careful shaping that standard proton therapy already does. A first trial of this precise form, for head and neck cancers that have come back after previous radiotherapy and cannot be removed by surgery, began in the United States in 2026. The first patient was treated in October 2026. It is a small feasibility trial, designed to test safety and whether the treatment can be delivered as planned — not to prove it works better. Larger trials, comparing FLASH directly with standard radiotherapy, have not yet been done. Until they are, nobody can say that FLASH protects healthy tissue better, or helps people live longer, than the treatments we already use.

What FLASH is not:

It is not a proven better treatment. The idea is promising, but the human evidence is early and small.

It is not a cure, and not a treatment for every cancer. So far it has only been tested in very specific situations — mainly painful bone metastases, and now re-treatment of head and neck cancer.

It is not widely available. FLASH is only offered inside clinical trials, at a small number of centres — mainly in the United States. It is not a routine treatment anywhere, including in Singapore.

It is not simply ‘faster radiotherapy’. The speed is the point — the hope is that the speed itself changes how healthy tissue responds. A quicker session on a standard machine is not FLASH.

Who might hear about FLASH?

You are most likely to hear about FLASH if:

  • Your cancer has spread to the bone and is causing pain, and your team mentions a trial.
  • Your cancer has come back in an area that has already had radiotherapy, and re-treatment is being considered.
  • You are reading about new radiotherapy developments, or a trial is advertised.

If a trial is suggested to you, your team will explain what it involves, what is known and unknown, and what the alternatives are. Taking part in a trial is always your choice, and you can leave a trial at any time.

What would taking part in a trial involve?

Trials of FLASH are still at an early stage, so they are small and careful. Typically, taking part involves:

  • Screening — scans and tests to check whether you fit the trial’s criteria, and whether FLASH is safe for your situation.
  • Consent — a full discussion of the risks, the unknowns, and what follow-up is needed, before you decide.
  • Treatment — usually a single FLASH session, or a small number of sessions over about a week or two.
  • Close follow-up — regular clinic visits and scans, often for longer than with standard treatment, because the team is still learning about side effects.

Because these trials are still testing safety and feasibility, they usually enrol only a small number of people, and only for the specific situations the trial is designed for.

Questions to ask your team:

  • Is FLASH relevant to my cancer, or is it only being studied for other situations?
  • Is there a FLASH trial I could join, and where would I need to go?
  • What would the trial involve, and what are the risks and unknowns?
  • How does it compare with the standard treatment I could have instead?
  • If I join a trial and it does not help, what are my other options?
  • How long would I need to stay near the trial centre, and what would it cost?

The bottom line:

FLASH is a genuinely interesting idea: the same radiation, delivered so fast that healthy tissue may be spared while the tumour is still treated. The animal results are encouraging, and the first small trials in people show that FLASH can be given safely. But the human evidence is still very early — small numbers, no direct comparison with standard radiotherapy yet, and no proof of better results. For now, FLASH is research, not routine care. If it lives up to its promise, it could one day help people whose tumours are hard to treat safely — but that day has not arrived yet, and your team can help you judge whether a trial is right for you.

This article is general information for patients and families. It does not replace advice from your own doctor, nurse, or radiographer. If you are unsure whether a FLASH trial could be relevant for you, please ask your treating team.

About the Author

Dr Wong Ru Xin

Dr Wong Ru Xin is a Radiation Oncologist at Icon Cancer Centre Singapore and a Visiting Consultant at Proton Therapy SG. She earned her MBBS from the National University of Singapore (Dean's List), and holds FRCR and MRCS qualifications. She completed specialist training at the National Cancer Centre Singapore.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these